Stroke; a journal of cerebral circulation
-
Randomized Controlled Trial Multicenter Study Comparative Study
Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial.
In Rivaroxaban Once Daily Oral Direct Factor Xa Inhibitor Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial, rivaroxaban was noninferior to dose-adjusted warfarin in preventing stroke or systemic embolism among patients with nonvalvular atrial fibrillation at moderate to high stroke risk. Because of differences in patient demographics, epidemiology, and stroke risk management in East Asia, outcomes and relative effects of rivaroxaban versus warfarin were assessed to determine consistency among East Asians versus other ROCKET AF participants. ⋯ http://www.clinicaltrials.gov. Unique identifier: NCT00123456.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Drivers of costs associated with reperfusion therapy in acute stroke: the Interventional Management of Stroke III Trial.
The Interventional Management of Stroke (IMS) III study tested the effect of intravenous tissue-type plasminogen activator (tPA) alone when compared with intravenous tPA followed by endovascular therapy and collected cost data to assess the economic implications of the 2 therapies. This report describes the factors affecting the costs of the initial hospitalization for acute stroke subjects from the United States. ⋯ http://www.clinicaltrials.gov. Unique identifier: NCT00359424.